CN Mobile Logo

Search form


Breast Cancer

70-Gene Signature Could Help Early-Stage Breast Cancer Patients Avoid Chemotherapy

Using a 70-gene signature test could identify many women with early-stage breast cancer considered to be at high clinical risk who do not actually need chemotherapy. Image © anyaivanova / Shutterstock.com.

Breast Cancer

Common breast cancer risk alleles are correlated with both the incidence of breast cancer and mortality, and using these alleles along with other factors could identify women at very low risk of breast cancer who could potentially avoid mammography.

Response to the HER2-targeted therapies lapatinib and trastuzumab are correlated with pathway-level genetic alterations, but not specific gene mutations.

Venous thromboembolism is significantly more likely over the long term in breast cancer patients than in the general population, according to a study in Sweden.

Here we review current guidelines on breast and ovarian cancer screening, prophylactic surgery, and other risk-reduction strategies in patients with these mutations, and we detail the data that drive these recommendations.

For some time, genetic testing has been predictive and prognostic. It is now assuming a therapeutic role as well. An example is the targeting of breast cancer patients with BRCA mutations for treatment with PARP inhibitors.

Brain metastasis remains a relatively common and particularly devastating complication of breast cancer and has proven a particularly challenging area for therapeutic innovation.


Subscribe to Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.